RVTY

Revvity, Inc. NYSE

Healthcare ·Medical - Diagnostics & Research ·US · revvity.com

$86.51

Pre-mkt $86.55 +0.01%

Mkt Cap $9.7B

52w Low $81.22 14.3% of range 52w High $118.30

50d MA $90.32 200d MA $94.36

P/E (TTM) 41.7x

EV/EBITDA 20.5x

P/B 1.4x

Debt/Equity 0.5x

ROE 3.3%

P/FCF 21.6x

RSI (14) —

ATR (14) —

Beta 1.13

50d MA $90.32

200d MA $94.36

Avg Volume 1.2M

About

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance… Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 2, 2026	BMO	1.57	1.70	+8.3%	107.09	+1.7%	-5.6%	-3.0%	-7.1%	-5.1%	-4.0%	-8.0%	—
Oct 27, 2025	BMO	1.14	1.18	+3.5%	97.16	+1.2%	-0.7%	-1.9%	-6.3%	-3.7%	-4.3%	+7.7%	—
Jul 28, 2025	BMO	1.14	1.18	+3.5%	95.04	-0.2%	-0.6%	-4.4%	-7.5%	-7.2%	-7.1%	-6.8%	—
Apr 28, 2025	BMO	0.96	1.01	+5.2%	95.06	-0.1%	-0.4%	-1.7%	-2.3%	-1.1%	-2.3%	-3.9%	—
Jan 31, 2025	BMO	1.37	1.42	+3.6%	126.13	-0.3%	-1.9%	-2.4%	-3.0%	-5.5%	-5.8%	-12.5%	—
Nov 4, 2024	BMO	1.13	1.28	+13.3%	124.82	-1.2%	+0.9%	+0.0%	-0.7%	-1.9%	-3.3%	-7.0%	—
Jul 29, 2024	BMO	1.12	1.22	+8.9%	125.59	+0.3%	+1.3%	+0.0%	-0.4%	-1.8%	-4.3%	-3.4%	—
Apr 29, 2024	BMO	0.94	0.98	+3.9%	105.02	-0.7%	-2.4%	-2.3%	-3.8%	-4.2%	-2.1%	+4.5%	—
Feb 1, 2024	BMO	1.15	1.25	+8.7%	109.26	-0.4%	-3.3%	-4.9%	-4.6%	-5.8%	-5.5%	-0.7%	—
Oct 30, 2023	BMO	1.19	1.18	-0.8%	82.08	+0.5%	+0.9%	+0.6%	+2.3%	+7.4%	+4.2%	+8.9%	—
Aug 1, 2023	BMO	1.18	1.21	+2.5%	122.63	-1.4%	+2.0%	+0.4%	+0.5%	+0.1%	+0.4%	-4.6%	—
May 11, 2023	BMO	1.06	1.01	-4.7%	118.37	-0.8%	-1.7%	-2.6%	-3.5%	-2.6%	-1.3%	-4.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 14	Barclays	Downgrade	Overweight → Equal Weight	—	$92.64	$92.50	-0.2%	+0.9%	+0.3%	-3.4%	+1.4%	+0.4%
Apr 14	Goldman Sachs	Maintains	Neutral → Neutral	—	$92.64	$92.50	-0.2%	+0.9%	+0.3%	-3.4%	+1.4%	+0.4%
Mar 31	JP Morgan	Maintains	Neutral → Neutral	—	$84.78	$86.20	+1.7%	+3.3%	+3.7%	+4.9%	+4.2%	+3.6%
Feb 3	JP Morgan	Maintains	Neutral → Neutral	—	$107.09	$108.91	+1.7%	-5.6%	-3.0%	-7.1%	-5.1%	-4.0%
Feb 3	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$107.09	$108.91	+1.7%	-5.6%	-3.0%	-7.1%	-5.1%	-4.0%
Feb 3	Evercore ISI	Maintains	Outperform → Outperform	—	$107.09	$108.91	+1.7%	-5.6%	-3.0%	-7.1%	-5.1%	-4.0%
Feb 3	Jefferies	Maintains	Hold → Hold	—	$107.09	$108.91	+1.7%	-5.6%	-3.0%	-7.1%	-5.1%	-4.0%
Feb 3	Barclays	Maintains	Overweight → Overweight	—	$107.09	$108.91	+1.7%	-5.6%	-3.0%	-7.1%	-5.1%	-4.0%
Feb 3	TD Cowen	Maintains	Buy → Buy	—	$107.09	$108.91	+1.7%	-5.6%	-3.0%	-7.1%	-5.1%	-4.0%
Dec 15	Barclays	Maintains	Overweight → Overweight	—	$100.49	$100.03	-0.5%	-1.4%	-4.2%	-3.7%	-4.2%	-4.2%
Dec 15	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$100.49	$100.03	-0.5%	-1.4%	-4.2%	-3.7%	-4.2%	-4.2%
Oct 28	Barclays	Maintains	Overweight → Overweight	—	$97.16	$98.33	+1.2%	-0.7%	-1.9%	-6.3%	-3.7%	-4.3%
Oct 28	Baird	Maintains	Outperform → Outperform	—	$97.16	$98.33	+1.2%	-0.7%	-1.9%	-6.3%	-3.7%	-4.3%
Oct 7	Evercore ISI	Maintains	Outperform → Outperform	—	$93.38	$93.80	+0.4%	-2.3%	-1.7%	-1.8%	-5.5%	-2.6%
Oct 2	Barclays	Maintains	Overweight → Overweight	—	$91.76	$90.54	-1.3%	-0.3%	+2.5%	+1.8%	-0.6%	+0.0%
Sep 22	BofA Securities	Maintains	Buy → Buy	—	$86.72	$85.93	-0.9%	-0.5%	-1.2%	-2.6%	-4.2%	-3.1%
Jul 29	Raymond James	Maintains	Outperform → Outperform	—	$95.04	$94.84	-0.2%	-0.6%	-4.4%	-7.5%	-7.2%	-7.1%
Jul 29	Stifel	Maintains	Hold → Hold	—	$95.04	$94.84	-0.2%	-0.6%	-4.4%	-7.5%	-7.2%	-7.1%
Jul 8	Evercore ISI	Maintains	Outperform → Outperform	—	$98.71	$98.83	+0.1%	+2.0%	+1.4%	+3.7%	+2.8%	-0.2%
Jun 26	BofA Securities	Maintains	Buy → Buy	—	$97.70	$98.18	+0.5%	+1.1%	+0.1%	-1.0%	+1.4%	+3.3%
May 1	UBS	Upgrade	Neutral → Buy	—	$93.43	$94.89	+1.6%	-0.6%	+0.6%	-0.6%	-3.2%	-2.0%
Apr 29	JP Morgan	Maintains	Neutral → Neutral	—	$95.06	$94.92	-0.1%	-0.4%	-1.7%	-2.3%	-1.1%	-2.3%
Apr 29	Raymond James	Maintains	Outperform → Outperform	—	$95.06	$94.92	-0.1%	-0.4%	-1.7%	-2.3%	-1.1%	-2.3%
Apr 29	Baird	Maintains	Outperform → Outperform	—	$95.06	$94.92	-0.1%	-0.4%	-1.7%	-2.3%	-1.1%	-2.3%
Apr 29	Goldman Sachs	Maintains	Buy → Buy	—	$95.06	$94.92	-0.1%	-0.4%	-1.7%	-2.3%	-1.1%	-2.3%
Apr 21	Baird	Maintains	Outperform → Outperform	—	$91.82	$90.88	-1.0%	-2.2%	+0.6%	+2.0%	+3.6%	+2.7%
Apr 17	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$93.75	$93.25	-0.5%	-2.1%	-4.2%	-1.5%	-0.1%	+1.5%
Apr 10	Barclays	Maintains	Overweight → Overweight	—	$101.34	$99.00	-2.3%	-8.2%	-6.4%	-3.7%	-5.7%	-7.5%
Feb 3	Barclays	Maintains	Overweight → Overweight	—	$126.13	$125.74	-0.3%	-1.9%	-2.4%	-3.0%	-5.5%	-5.8%
Feb 3	Raymond James	Maintains	Outperform → Outperform	—	$126.13	$125.74	-0.3%	-1.9%	-2.4%	-3.0%	-5.5%	-5.8%
Feb 3	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$126.13	$125.74	-0.3%	-1.9%	-2.4%	-3.0%	-5.5%	-5.8%
Jan 21	Raymond James	Maintains	Outperform → Outperform	—	$118.39	$119.02	+0.5%	+4.7%	+3.7%	+3.9%	+4.0%	+4.8%
Dec 13	BofA Securities	Upgrade	Neutral → Buy	—	$116.01	$116.71	+0.6%	-0.1%	-0.7%	-1.1%	-5.9%	-4.7%
Nov 25	Barclays	Maintains	Overweight → Overweight	—	$112.03	$113.00	+0.9%	+2.3%	+2.7%	+3.7%	+3.7%	+4.2%
Nov 5	TD Cowen	Maintains	Buy → Buy	—	$124.82	$123.29	-1.2%	+0.9%	+0.0%	-0.7%	-1.9%	-3.3%
Nov 5	Baird	Maintains	Outperform → Outperform	—	$124.82	$123.29	-1.2%	+0.9%	+0.0%	-0.7%	-1.9%	-3.3%
Nov 5	Raymond James	Maintains	Outperform → Outperform	—	$124.82	$123.29	-1.2%	+0.9%	+0.0%	-0.7%	-1.9%	-3.3%
Nov 5	Bernstein	Maintains	Outperform → Outperform	—	$124.82	$123.29	-1.2%	+0.9%	+0.0%	-0.7%	-1.9%	-3.3%
Oct 17	Leerink Partners	Maintains	Outperform → Outperform	—	$120.18	$121.70	+1.3%	-0.9%	-0.4%	-0.8%	-1.2%	-1.4%
Oct 15	Barclays	Upgrade	Equal Weight → Overweight	—	$122.91	$124.61	+1.4%	+1.2%	-2.2%	-3.1%	-2.6%	-3.0%
Jul 30	Citigroup	Maintains	Buy → Buy	—	$125.59	$126.02	+0.3%	+1.3%	+0.0%	-0.4%	-1.8%	-4.3%
Jul 30	JP Morgan	Maintains	Neutral → Neutral	—	$125.59	$126.02	+0.3%	+1.3%	+0.0%	-0.4%	-1.8%	-4.3%
Jul 30	BofA Securities	Maintains	Neutral → Neutral	—	$125.59	$126.02	+0.3%	+1.3%	+0.0%	-0.4%	-1.8%	-4.3%
Jul 30	TD Cowen	Maintains	Buy → Buy	—	$125.59	$126.02	+0.3%	+1.3%	+0.0%	-0.4%	-1.8%	-4.3%
Jul 30	Barclays	Maintains	Equal Weight → Equal Weight	—	$125.59	$126.02	+0.3%	+1.3%	+0.0%	-0.4%	-1.8%	-4.3%
Jul 29	Jefferies	Maintains	Hold → Hold	—	$115.15	$121.44	+5.5%	+9.1%	+10.4%	+9.1%	+8.6%	+7.1%
Jun 28	Barclays	Maintains	Equal Weight → Equal Weight	—	$105.71	$105.62	-0.1%	-0.8%	-2.6%	-3.5%	-3.0%	-2.0%
Apr 30	TD Cowen	Maintains	Buy → Buy	—	$105.02	$104.30	-0.7%	-2.4%	-2.3%	-3.8%	-4.2%	-2.1%
Apr 30	Baird	Maintains	Outperform → Outperform	—	$105.02	$104.30	-0.7%	-2.4%	-2.3%	-3.8%	-4.2%	-2.1%
Feb 2	Stifel	Maintains	Hold → Hold	—	$109.26	$108.79	-0.4%	-3.3%	-4.9%	-4.6%	-5.8%	-5.5%

Recent Filings

8-K · 2.02 !! High

Revvity, Inc. -- 8-K 2.02: Earnings Results

Revvity reported Q1 2026 earnings on May 5, 2026, providing investors with updated financial performance metrics for the quarter ended April 5, 2026.

May 5

8-K

Revvity, Inc. -- 8-K Filing

Revvity reported Q4 2025 revenue of $772 million with 6% growth and adjusted EPS of $1.70, while initiating 2026 guidance to support investor forward planning.

Feb 2

Data updated apr 26, 2026 11:45pm · Source: massive.com